šŸŽ Black Friday: 50% off Unlimited and 30% off Pro annual plans
ProKidney Corp. (PROK)
NASDAQ: PROK Ā· Real-Time Price Ā· USD
1.040
-0.020 (-1.89%)
At close: Nov 20, 2026, 4:00 PM EST
1.030
-0.010 (-0.94%)
After-hours: Nov 20, 2026, 7:23 PM EST
← View all transcripts

Jefferies Global Healthcare Conference

Nov 16, 2026

Summary

Rilparencel’s phase III accelerated-approval readout is expected in Q2 2027, with confirmatory results currently projected for H2 2029. Initial manufacturing capacity is planned at 350 doses annually at launch, with expansion plans thereafter.

Andrew Tsai
Senior Biotech Analyst, Jefferies

All right. I'm Andrew Tsai, Senior Biotech Analyst at Jefferies. Thanks for joining me today, and it's my pleasure to have the ProKidney team with me. To my direct right, Bruce Culleton, CEO. To his right is James Coulston, CFO. And to James' right is Anthony Conway, VP, or head of IR. Welcome, all of you. Head of R&D?

Anthony Conway
Head of R&D, ProKidney

R&D, yeah.

Andrew Tsai
Senior Biotech Analyst, Jefferies

Okay, yes. Good. And so maybe give us an introduction about ProKidney for those who are less familiar with the story. What you're working on, what you're trying to achieve, what milestones we can expect over the next 6-12 months.

Bruce Culleton
CEO, ProKidney

Yeah. Sounds good, Andrew, and thanks for inviting us to the meeting. ProKidney is a company that's based in the U.S. We've got the majority of our employees in North Carolina. We have 250 employees. Everyone is aligned, I think, to a single purpose, and that single purpose is to help patients who've got diabetes and advanced chronic kidney disease to delay the onset of dialysis or the need for a transplant. We have a product, a single product. It's an autologous cell therapy. It's called rilparencel. And we are fortunate enough to be well into our phase III clinical study. On the background of good phase II data, we finished enrollment, we finished recruitment in August. We anticipate finishing enrollment in Q1, and we expect accelerated approval readout on a surrogate endpoint in Q2 of 2027.

Andrew Tsai
Senior Biotech Analyst, Jefferies

Perfect. So maybe to level set the market opportunity, remind us the drugs approved for non-dialysis type 2 diabetes patients with non-dialysis CKD stage 3B, four, or stage 3B4. How big is the population? What drugs are currently used at the moment?

Bruce Culleton
CEO, ProKidney

The population, just in the U.S. alone, there are about 1 million patients who have advanced chronic kidney disease. That is late stage 3B or stage 4 chronic kidney disease. And those 1 million patients today have seen significant advances in the treatment of diabetic kidney disease over the last five years. So right now, if you are a treating physician, you have four pillars of therapeutic options that you could choose from. The older drugs are renin-angiotensin system inhibitors, ACE inhibitors, and ARBs, for example. SGLT2 inhibitors are now approved. We have non-steroidal MRAs and GLP-1s. So definitely a forward advance in how we treat patients with chronic kidney disease and diabetes. But we also understand, and this is consistent across all those products and all the clinical data that is behind them, is that some patients continue to progress.

If you look at the data from each trial, there is a residual risk, and that residual risk is shown by the fact that the risk of developing a kidney-related event or a cardiovascular event is still greater than the benefit that you see with the drug. So that speaks to the residual risk. Where we think we really fit in is knowing that some of these patients continue to progress and will end up on dialysis at some point in time. We are really there, we are positioning our therapy for those patients who are on standard of care and continue to progress. And that market is going to be a sub-fraction of the 1 million, but we still believe it is going to be a substantial market.

Andrew Tsai
Senior Biotech Analyst, Jefferies

As a one to two-time cell therapy, it is not a chronic therapy, to be clear.

Bruce Culleton
CEO, ProKidney

That's correct, Andrew, and so very good point there. All the other agents I mentioned, patients have to wake up every day and take those medications. If you're a diabetic with chronic kidney disease and your GFR is around 30, then you often have multiple comorbidities. You're often on a lipid-lowering agent, maybe multiple antihypertensives, maybe something to control edema, vitamin D, maybe an oral iron drug. I could go on. The average might be eight to 10 to 12 drugs on a daily basis. With rilparencel, you get two injections. You get one injection after the product is made, and three months later, you get an injection in the other kidney. First is in the biopsied kidney, and the other injection's in the contralateral kidney.

Andrew Tsai
Senior Biotech Analyst, Jefferies

Understood. What's the latest on your payer work? Because when I think cell therapy, you could price it very high. This is also a million patient population. What does it take to get a billion in peak sales in terms of price?

Bruce Culleton
CEO, ProKidney

Yeah, I'm going to ask James to have a go at that answer. James, if you don't mind.

James Coulston
CFO, ProKidney

Sure. Yeah, so I think when we think about pricing, we can think about it from a couple of different perspectives. First is the value, the potential value that rilparencel could bring to the U.S. healthcare system. Dialysis costs the U.S. healthcare system for patients that are covered by Medicare $100,000 annually. For patients that are covered by private payers, it can cost two or more times that amount. So one way to think about it is for every year rilparencel is able to stabilize kidney function and keep patients off of dialysis, that could deliver $200,000 of value or savings to the U.S. healthcare system. A couple of other ways to think about it is just by recent comps. Other recently launched cell therapies have launched in the $400,000-$500,000 range.

And also other recently launched treatments for other kidney diseases, IgAN as an example, have also launched in the $400,000-$500,000 range. That is an annual cost, so that would likely be a lifetime annual cost going forward. If you look at those, both the figures I gave you, which is potential savings to the U.S. healthcare system as well as comps, you can start to narrow in on what pricing might look like.

Andrew Tsai
Senior Biotech Analyst, Jefferies

Thanks. And-

Bruce Culleton
CEO, ProKidney

Andrew, if I could, if you do not mind-

Andrew Tsai
Senior Biotech Analyst, Jefferies

Yeah.

Bruce Culleton
CEO, ProKidney

Just to, James, to add on something like that, just given the fact that we are in the U.K. I will say that dialysis costs a lot of money wherever you look across the world. There are some countries, like the U.S., that is definitely in the top tier of what is paid for dialysis, but there are other countries, some countries in Europe, that actually pay more than what the U.S. pays for dialysis, and there are a lot of countries that pay less as well. I will also say that, just to put the patient forward here too, dialysis has a huge impact on patients. Many patients go to dialysis three times per week. Most end up stopping to work because they cannot go to dialysis and continue to work. Many of them have out-of-pocket costs.

Many require caretakers, which often turns out to be a spouse or a daughter or a son, and then they're out of work. So the impact on society is far more than just what the payer pays for a product.

Andrew Tsai
Senior Biotech Analyst, Jefferies

Makes sense. And so, recently, at ASN Kidney Week, you shared some interesting data to help explain the mechanism of rilparencel. So can you kind of give us the key takeaways?

Anthony Conway
Head of R&D, ProKidney

Yeah, absolutely.

Andrew Tsai
Senior Biotech Analyst, Jefferies

How this works?

Anthony Conway
Head of R&D, ProKidney

At ASN, we had seven non-clinical presentations, including an oral presentation. Four of those were on our new mechanism of action work and three on drug product characterization. Across all of our different CKD translational models, spanning from in vitro, ex vivo, as well as rodent models, what we are observing in all of these different models is an attenuation of oxidative damage, metabolic dysregulation, pro-inflammatory signaling to promote functional stabilization of both endothelial cells comprising the blood vessels, as well as epithelial cells comprising the tubules. What we are observing in our rodent models is rilparencel, after being injected into the kidney cortex, it is engrafting most consistently at the highest density in the subcapsular region, but the effects that we are seeing are more systemic, indicative of a paracrine mechanism.

The cells that rilparencel is secreting is going into circulation and promoting more systemic therapeutic response.

Andrew Tsai
Senior Biotech Analyst, Jefferies

Great. Let us talk about your ongoing pivotal trial. Like you said, the first readout in Q2 of next year is for an accelerated approval based on eGFR. Remind us how you powered the study on both the drug versus sham side of things.

Bruce Culleton
CEO, ProKidney

We made some assumptions, as you always do when you are powering a study. We assumed in the sham group of a 3 mL per minute decline in kidney function on an annual basis. We drew that information largely from a meta-analysis, which included well over 100,000 patients. The treatment effect that we are assuming with rilparencel is a decline in kidney function of 1.5 mLs per minute per year. That is a little bit higher than what we have seen in one of our phase II trials, but we are making some very conservative estimates here. In this power assumption, we are assuming a benefit of 1.5 mLs per minute delta between the two groups. In a phase II trial that we presented last year, we saw a 4.5 mL per minute difference between the two groups. Very conservative assumptions.

The study is powered using the assumptions I just outlined at 80% to detect that 1.5 ml per minute difference.

Andrew Tsai
Senior Biotech Analyst, Jefferies

80%. Based on that phase II data, the FDA gave you guys an RMAT designation. I do not think there was a Was there a sham? Sorry. Or was it open label?

Bruce Culleton
CEO, ProKidney

So-

Andrew Tsai
Senior Biotech Analyst, Jefferies

That was pretty open.

Bruce Culleton
CEO, ProKidney

There was no sham involved in the RMAT designation. The RMAT designation is really based upon, you need to have a product that is a gene therapy or cell therapy, essentially. You need to be treating a disease or condition where you can have an impact on the cure or substantially change the outcome of that condition, and you need to have preliminary data. The preliminary data that we used, you are right, Andrew, has come from the phase II data, originally from the RMCL-002 data, not the REGEN-007 data. The RMCL-002 data is where we saw a big impact on patients with significant and advanced chronic kidney disease.

Andrew Tsai
Senior Biotech Analyst, Jefferies

Okay. One more time, as you powered it for that, the drug reduces by 1.5 annualized on the eGFR slope. In the prior phase II, you saw something better than that, which is actually a less negative value. I always have to rethink this every time. The point is, it was a conservative assumption on the drug side. On the sham side, you just said 3.0. How did you kind of model off of the sham?

Bruce Culleton
CEO, ProKidney

Yeah. That was based upon a Lesley Inker meta-analysis in Nature Medicine. In that meta-analysis, I think of over 180,000 people with diabetes and chronic kidney disease, there was an average decline of three mLs per minute. What we've seen in our other phase II, just to be clear, other two phase II studies, is we saw a greater decline in untreated patients than three mLs per minute. We saw a decline in the range of five to six. There's a couple of reasons why we might be seeing a greater decline in our phase II population in the untreated patients. We speculate that physicians are treating patients who are already progressing. They're already on the best standard of care, and it's those patients that continue to progress that demonstrate that unmet need that are being picked by physicians to enroll in our phase III program.

Andrew Tsai
Senior Biotech Analyst, Jefferies

I see. So, one difference between the phase II and phase III is maybe these patients are. More phase III patients are technically on standard care, so rather than five to six, maybe it's closer to three is your point.

Bruce Culleton
CEO, ProKidney

They might be, but actually we believe that even in our phase III, like we saw in our phase II, that it's the patients who are progressing are at greatest risk that the physicians are choosing to enroll in the study because standard of care doesn't seem to be working for them.

Andrew Tsai
Senior Biotech Analyst, Jefferies

Okay. Just more of a technicality question. I think the phase III has enrolled, is it over 300 patients at the moment?

Bruce Culleton
CEO, ProKidney

The phase III trial has enrolled more than that actually. Just to give some perspective, we have already enrolled the 320 patients needed for the accelerated approval readout, and we continue to enroll more patients based upon patients that were screened up until early August. So, we anticipate the overall total population to be included in this study to be well north of 500 patients.

Andrew Tsai
Senior Biotech Analyst, Jefferies

Makes sense. For the accelerated approval analysis, it will be on that 320.

Bruce Culleton
CEO, ProKidney

Correct.

Andrew Tsai
Senior Biotech Analyst, Jefferies

Furthermore, will the analysis be based on that group or the subset of patients who are both biopsy and actually treated? What do you anticipate that number to be?

Bruce Culleton
CEO, ProKidney

Yeah. The 320 includes patients who received at least one injection.

Andrew Tsai
Senior Biotech Analyst, Jefferies

Oh, okay.

Bruce Culleton
CEO, ProKidney

Yeah. That is the 320. That is what is going to be included in the accelerated approval readout. In the confirmatory readout, that includes everyone, which will be north of 500 patients.

Andrew Tsai
Senior Biotech Analyst, Jefferies

Very clear. Have there been any changes in the formulation or the manufacturing side between phase II and phase III, as I think about you trying to replicate what you saw in phase II?

Bruce Culleton
CEO, ProKidney

There was a difference in manufacturing, slight difference, going from one of our phase II studies to the REGEN-007 study. We actually changed from a fresh product to a cryopreserved product. We made sure that the product that we were making was essentially the same product. That product was used in REGEN-007. That cryopreserved process is what we are also using in our phase III program.

Andrew Tsai
Senior Biotech Analyst, Jefferies

Got it. You mentioned these 320 patients, at least one injection. What proportion could have two injections? Would two get you better efficacy than one, for instance?

Bruce Culleton
CEO, ProKidney

Well, we think two gets us better efficacy because we are injecting into the other kidney for the second one. The dropout between first injection and second injection is less than 3%. There is very little dropout going from first injection to second injection.

Andrew Tsai
Senior Biotech Analyst, Jefferies

I see. 97% of patients generally should have both injections.

Bruce Culleton
CEO, ProKidney

Correct.

Andrew Tsai
Senior Biotech Analyst, Jefferies

Okay. Very good. On the safety side, after efficacy is pretty clear, on the safety front, what kind of special AEs are you specifically looking for? Have you seen any SAEs on a blinded basis?

Bruce Culleton
CEO, ProKidney

So, of course, in phase III, I am blinded to everything that is going on, so I do see safety events that come in. We are specifically interested in safety events associated with the kidney biopsy, because this is not a normal procedure. Even though it is frequently done in the kidney space, we are asking these patients to do this for the study, and then we inject them twice.

What we are looking for is any complication related to bleeding or infection specifically, right? As long as other complications, but those areas are where we are specifically looking. Then if there is any off-target effects, which we have not seen. So we do see some bleeding complications, no more than what you typically see with a standard kidney biopsy. We have seen very rarely a local hematoma form around the kidney injection. That is a very unusual event that happens with us.

Then, in general, the safety profile looks pretty good outside of, including the bleeding events.

Andrew Tsai
Senior Biotech Analyst, Jefferies

Oh, okay.

Bruce Culleton
CEO, ProKidney

The profile looks pretty strong.

Andrew Tsai
Senior Biotech Analyst, Jefferies

Can you remind me, in phase II, did you see any kind of severe events, and do you expect that in phase III?

Bruce Culleton
CEO, ProKidney

This population is going to have serious adverse events no matter what you're doing to them, just because they're sick, they've got lots of comorbidities. We're not seeing anything unusual in the SAEs that are being reported to us.

Andrew Tsai
Senior Biotech Analyst, Jefferies

Very clear. Okay, to wrap things up, the data sets in Q2, can you give us a teaser what you plan to share in the top-line release? How much data would we be getting?

Bruce Culleton
CEO, ProKidney

Well, I can tell you that I'd love to sit here and say that I'll share everything, that we'll share everything, but we can't do that. We've got to work with regulators. But what we can see is that for companies that are releasing interim data that's associated with accelerated approval, it's typically top-line efficacy. Maybe some secondary, a secondary endpoint of interest, but the primary efficacy for sure, and then an overall assessment of safety. But the details of which probably won't come out until ASN Kidney Week, which is later on in 2027, and we'd hope to get a simultaneous publication as well with that, where all the details will be shared.

Andrew Tsai
Senior Biotech Analyst, Jefferies

I see. And let's just say when the ASN 2027 happens in November, where we get more details, could that be the time where, as we talk about the next step of this trial, because right now it's accelerated approval based on eGFR, but you also have a time to composite event for full approval. Could we get a cut of that, actually?

Bruce Culleton
CEO, ProKidney

Again, I'd love to share that, but I don't think we can. Anytime we take a peek at that type of data, then we burn some alpha in doing so. We have no intents at looking at the confirmatory events based on study group until we actually hit that 122 events, which would be the number we're looking for the confirmatory analysis.

Andrew Tsai
Senior Biotech Analyst, Jefferies

And those events, what exactly are those, to be clear?

Bruce Culleton
CEO, ProKidney

Yeah. So it is a time to a composite, which is typical for this type of study, and it is time to the first of the following: greater than a 40% decrease in eGFR, a sustained eGFR less than 15, new onset chronic dialysis, a transplant, or renal and cardiovascular death. Just given the patient population that we are seeing, by far and away the greatest number of events that we are seeing are those related directly to eGFR, which gives us a lot of confidence that the eGFR slope data that we will see in Q2 of 2027 is going to translate directly into any event benefit we will see in the confirmatory readout.

Andrew Tsai
Senior Biotech Analyst, Jefferies

Understood. You just mentioned discontinuation rates should be very low.

Bruce Culleton
CEO, ProKidney

We are seeing very little discontinuation rate between first and second injection, and even after second injection, the discontinuation rate is pretty low. Keep in mind that they are not having to take any medications or any drugs after the second injection. They are just coming back for the routine follow-up.

Andrew Tsai
Senior Biotech Analyst, Jefferies

Right. So that dataset, eGFR, will be in Q2 of next year. The BLA filing, is it now early 2028?

Bruce Culleton
CEO, ProKidney

Yeah.

Andrew Tsai
Senior Biotech Analyst, Jefferies

The question would be why these many months?

Bruce Culleton
CEO, ProKidney

Why does it take so long? There's a little bit of work to do on the clinical side to package everything up for the BLA submission. I think we'll actually be ready on the clinical side earlier than Q1 2028. What we've actually recognized recently is because of the increase in demand, essentially, the recruitment that came in over the spring and summer into the study, we wanted to make sure that everyone that was eligible could get into the trial. That pushed out our enrollment from Q4 of this year to Q1 of next year. That means our manufacturing facility is still making product in Q1. That pushes out their timelines. They can't do some inspection-ready modifications to our site, some slight changes to the site to make it ready for inspection.

They can't do some of the final process validation work that needs to get done, and that's why it's pushed out into Q1 2028, which is, I still think, reasonably aggressive for the amount of work that needs to get done.

Andrew Tsai
Senior Biotech Analyst, Jefferies

Understood. Going back to the confirmatory, forgot to mention that dataset is second half of 2029. What kind of hazard ratio are you expecting?

Bruce Culleton
CEO, ProKidney

We assumed a difference between the two groups of essentially a hazard ratio of 0.6 between the two groups.

Andrew Tsai
Senior Biotech Analyst, Jefferies

Okay.

Bruce Culleton
CEO, ProKidney

That would be powered at 80% to detect that hazard ratio. I will say that the second half of 2029 is based upon an assumption of an event rate somewhere between 10 and 12 events per 100 patient years. We took that data from global studies, which included U.S. patients and included patients from Europe and Asia. It's possible that because we're including U.S. patients primarily in this study, that we may see a higher event rate, and therefore, less time to get to those 122 events.

Andrew Tsai
Senior Biotech Analyst, Jefferies

Mm-hmm. Thanks. As we look fast-forward a little bit as you're filing for this product, how are you preparing on the manufacturing front? Ultimately, how many doses per year do you think you'll be able to provide with your manufacturing?

Bruce Culleton
CEO, ProKidney

Yeah. We actually just released a little bit of information on this recently. James, do you mind talking about our capacity when we launch?

James Coulston
CFO, ProKidney

Yeah, sure. Right now, first of all, we own all of our own manufacturing. We manufacture all the product for our phase III in the same manufacturing facility that we've manufactured all the product for all of our clinical studies. We have the ability to plan to launch from that same facility. At launch, we expect that facility that we've been manufacturing in to be able to manufacture 350 doses or products for 350 patients annually. We've also purchased in an adjacent building, we've also built in an adjacent building that we also own, the first manufacturing facility that can also manufacture up to 500 product in a year. The construction on that is effectively done. We've still got some work to do on tech transfer and some other things. That'll come online likely after launch, maybe about a year after launch.

As we think about building out our capacity, it'll be 350 at launch, 500 about a year later. In addition, in that other building that we just started to build out in, we have additional space where we can continue to build out additional manufacturing rooms as we continue to grow. That additional space, coupled with the potential to look at potentially working other geographic areas, potentially working with CDMOs, we think we can get to 3,000 in a few years.

Andrew Tsai
Senior Biotech Analyst, Jefferies

Great.

Bruce Culleton
CEO, ProKidney

Andrew, that's well less than what number of patients who would need product, right? Assuming that we're successful. That's our current plans. For us to really scale, based upon really good data, for us to really scale, we'd need to dedicate some investment, whether that's dilutive or whether that's with partners or whether that's through debt or some other mechanism to actually scale up where we can actually treat more patients and help more patients in total.

Andrew Tsai
Senior Biotech Analyst, Jefferies

Okay. Then very last question in the last 30 seconds. Let's just say you did succeed here. Do you plan to move upstream with this product, or what's next?

Bruce Culleton
CEO, ProKidney

Right now we are focused solely on the advanced diabetic chronic kidney disease market. It is so big that I do not want to take focus away from us doing a good job in that market.

Andrew Tsai
Senior Biotech Analyst, Jefferies

Thank you very much. Appreciate the updates. Good luck on the data readout next year, and thanks everyone for listening.